Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Neoadjuvant Abemaciclib and Fulvestrant for HR+ Breast Cancer with Endocrine Resistance
NCT04305236Phase 2Terminated
- Sponsor
- University of California, Irvine
- Start
- Jul 2020
- Primary completion
- Feb 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of abemaciclib in Hormone-Receptor-Positive Breast Cancer, sponsored by University of California, Irvine. Started Jul 2020; status: terminated.
02
Drugs
abemaciclib
03
Conditions
Hormone-Receptor-Positive Breast Cancer
Beyond the preview
Go deeper on NCT04305236.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04305236.